EphrinB2 and EphB4 expression in pterygia: New insights and preliminary results

Canadian Journal of Ophthalmology

Volumn 44, Issue 2, 2009, Pages 185-188

  Xue, Chunyan ^a   Huang, Zhenping ^a   Wang, Jiandong ^b   Dong, Yingchun ^b   Zhou, Xiaojun ^b  

^a Department of Ophthalmology ^*

^b NANJING UNIVERSITY   (China)

Author keywords

EephrinB2; EphB4; Pterygium

Indexed keywords

EPHRIN B2; EPHRIN RECEPTOR B4;

ADULT; AGED; ARTICLE; CONJUNCTIVA; CONJUNCTIVA EPITHELIUM; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PTERYGIUM; TISSUE DISTRIBUTION;

EID: 66249131317     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/i09-005     Document Type: Article

References (35)

1. Di Girolamo N, Wakefield D, Coroneo MT. UVB-mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signaling. Invest Ophthalmol Vis Sci 2006;47:2430-7.
2. Memarzadeh F, Fahd AK, Shamie N, Chuck RS. Comparison of de-epithelialized amniotic membrane transplantation and conjunctival autograft after primary pterygium excision. Eye 2008;22:107-12.
3. Wong VW. Polyglactin sutures versus nylon sutures for suturing of conjunctival autograft in pterygium surgery: a randomized controlled trial-reply. Acta Ophthalmol Scand 2007;85:658-61.
4. Dushku N, Reid TW. P53 expression in altered limbal basal cells of pingueculae, pterygia, and limbal tumors. Curr Eye Res 1997;16:1179-92.
5. Tan DT, Lim AS, Goh HS, Smith DR. Abnormal expression of the p53 tumor suppressor gene in the conjunctiva of patients with pterygium. Am J Ophthalmol 1997;123:404-5.
6. Clear AS, Chirambo MC, Hutt MS. Solar keratosis, pterygium, and squamous cell carcinoma of the conjunctiva in Malawi. Br J Ophthalmol 1979;63:102-9.
7. Chiang CC, Cheng YW, Lin CL, et al. Cyclooxygenase 2 expression in pterygium. Mol Vis 2007;13:635-8.
8. Ramalho FS, Maestri C, Ramalho LN, Ribeiro-Silva A, Romao E. Expression of p63 and p16 in primary and recurrent pterygia. Graefes Arch Clin Exp Ophthalmol 2006;244:1310-4.
9. Lee DH, Cho HJ, Kim JT, Choi JS, Joo CK. Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea 2001;20:738-42.
10. Marcovich AL, Morad Y, Sandbank J, et al. Angiogenesis in pterygium: morphometric and immunohistochemical study. Curr Eye Res 2002;25:17-22.
11. Martiny-Baron G, Korff T, Schaffner F, et al. Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia 2004;6:248-57.
12. Muller-Ehmsen J, Schmidt A, Krausgrill B, Schwinger RH, Bloch W. Role of erythropoietin for angiogenesis and vasculogenesis: from embryonic development through adulthood. Am J Physiol Heart Circ Physiol 2006;290:H331-40.
13. Umeda N, Ozaki H, Hayashi H, Oshima K. Expression of ephrinb2 and its receptors on fibroproliferative membranes in ocular angiogenic diseases. Am J Ophthalmol 2004;138:270-9.
14. He S, Ding Y, Zhou J, et al. Soluble EphB4 regulates choroidal endothelial cell function and inhibits laser-induced choroidal neovascularization. Invest Ophthalmol Vis Sci 2005;46:4772-9.
15. Kojima T, Chung TY, Chang JH, Sayegh R, Casanova FH, Azar DT. Comparison of EphA receptor tyrosine kinases and ephrinA ligand expression to ephB-ephrinB in vascularized corneas. Cornea 2007;26:569-78.
16. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
17. Ozaki H, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA, Oshima K. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res 1997;64:505-17.
18. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the tie2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-80.
19. Hackett SF, Ozaki H, Strauss RW, et al. Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J Cell Physiol 2000;184:275-84.
20. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999;13:1055-66.
21. Patan S. Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling. J Neurooncol 2000;50:1-15.
22. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature (London) 2000;407:242-8.
23. Klein R. Eph/ephrin signaling in morphogenesis, neural development and plasticity. Curr Opin Cell Biol 2004;16:580-9.
24. Palmer A, Klein R. Multiple roles of ephrins in morphogenesis, neuronal networking, and brain function. Genes Dev 2003;17:1429-50.
25. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998;93:741-53.
26. Gerety SS, Wang HU, Chen ZF, Anderson DJ. Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 1999;4:403-14.
27. Liu W, Ahmad SA, Jung YD, et al. Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 2002;94:934-9.
28. Stephenson SA, Slomka S, Douglas EL, Hewett PJ, Hardingham JE. Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer. BMC Mol Biol 2001;2:15.
29. Wu Q, Lind GE, Aasheim HC, et al. The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers. Epigenetics 2007;2:237-43.
30. Kria L, Ohira A, Amemiya T. Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium. Acta Histochem 1996;98:195-201.
31. Kertesz N, Krasnoperov V, Reddy R, et al. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-ephrinb2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood 2006;107:2330-8.
32. Perra MT, Maxia C, Corbu A, et al. Oxidative stress in pterygium: relationship between p53 and 8-hydroxydeoxyguanosine. Mol Vis 2006;12:1136-42.
33. Kim I, Ryu YS, Kwak HJ, et al. EphB ligand, ephrinB2, suppresses the VEGF- and angiopoietin 1-induced Ras/mitogenactivated protein kinase pathway in venous endothelial cells. FASEB J 2002;16:1126-8.
34. Hainaud P, Contreres JO, Villemain A, et al. The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4- ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res 2006;66:8501-10.
35. Kumar SR, Singh J, Xia G, et al. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol 2006;169:279-93.